Document

Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases

The Department of Health and Human Services, National Institutes of Health published a Notice in the Federal Register on August 5, 2025. That notice requires a correction in the...

PDF version Source Record

Department of Health and Human Services

National Institutes of Health

AGENCY:

National Institutes of Health, HHS.

ACTION:

Notice; correction.

SUMMARY:

The Department of Health and Human Services, National Institutes of Health published a Notice in the Federal Register on August 5, 2025. That notice requires a correction in the SUPPLEMENTARY INFORMATION section.

DATES:

Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 9, 2026 will be considered.

ADDRESSES:

Inquiries and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)-276-5484; Email: andy.burke@nih.gov.

SUPPLEMENTARY INFORMATION:

Correction

In the Federal Register of February 13, 2026, in FR Doc. 2026-02907, on page 6864, as found within the SUPPLEMENTARY INFORMATION section. Currently reads:

“The development, production, and commercialization of an anti-CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy using a:

1. non-viral synthetic nanoparticle-based system, or

2. viral system (excluding lentiviral)

that encapsulates mRNA or DNA encoding a CAR having the complementary determining region (CDR) sequences of the anti-CD19 scFv known as Hu19, for the treatment or prevention of autoimmune diseases. And is corrected to read:

“The development, production, and commercialization of an anti-CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy using a:

3. non-viral synthetic nanoparticle-based system, or

4. viral system

that encapsulates mRNA or DNA encoding a CAR having the complementary determining region ( printed page 8262) (CDR) sequences of the anti-CD19 scFv known as Hu19, for the treatment or prevention of autoimmune diseases.

Alycia Booth,

NIH Federal Register Certifying Official, National Institutes of Health.

[FR Doc. 2026-03337 Filed 2-19-26; 8:45 am]

BILLING CODE 4140-01-P

Legal Citation

Federal Register Citation

Use this for formal legal and research references to the published document.

91 FR 8261

Web Citation

Suggested Web Citation

Use this when citing the archival web version of the document.

“Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases,” thefederalregister.org (February 20, 2026), https://thefederalregister.org/documents/2026-03337/prospective-grant-of-an-exclusive-patent-license-in-vivo-manufactured-anti-cd19-chimeric-antigen-receptor-car-products-f.